

硫脲衍生物有机催化蒽酮与硝基烯烃的 不对称 Michael 加成反应

王黎明, 陈 哲, 赵美君, 金 瑛*

(吉林医药学院 药学院, 吉林 吉林 132013)

摘要: 将硫脲衍生物用于有机催化蒽酮和 β -硝基烯烃的不对称 Michael 加成反应. 考察溶剂、温度及催化剂用量等对反应催化性能的影响. 结果表明, 最佳催化条件为 5% (摩尔百分数) 催化剂 **1f**, 二氯甲烷为溶剂, 室温反应. 得到了 80%~97% 的化学产率和最高达 99% ee 的对映选择性.

关键词: 硫脲衍生物; 有机催化; 不对称 Michael 加成反应; 蒽酮; β -硝基烯烃

中图分类号: O621.3

文献标志码: A

Michael 加成反应是一种高效的构建 C—C 键的重要方法^[1-3]. 近年来, 有机小分子催化的不对称 Michael 反应引起了广泛关注^[4-7]. 脲/硫脲衍生物由于具有很强的氢键活化能力, 成功的实现了对多种反应的高对映选择性催化, 尤其在各类底物的不对称 Michael 加成反应中取得了很大进展^[8-25]. 然而, 蒽酮化合物作为亲核试剂在不对称 Michael 加成反应的文献报道较少^[26-30]. 2007 年, Shi 首次报道了金鸡纳碱有机催化的蒽酮与 β -硝

基烯烃的不对称 Michael 加成反应, 得到了 80%~99% ee 的对映选择性^[27]. 2009 年, Yuan 报道了叔胺硫脲类有机催化剂在该反应中的应用, 得到了 60%~94% ee 的立体选择性^[28]. 2010 年 He 报道了伯胺硫脲有机催化蒽酮不对称 Michael 加成反应, 得到了 65%~86% 的对映选择性^[29]. 这里我们报道系列脲/硫脲催化剂 **1a-g** (Fig.1) 有机催化蒽酮与 β -硝基苯烯烃的不对称 Michael 加成反应, 以期扩大该反应的催化剂类型.




图 1 催化剂 **1a-g** 的结构

Fig.1 The structures of catalysts **1a-g**

收稿日期: 2018-01-05; 修回日期: 2018-02-15.

基金项目: 国家自然科学基金(21102055), 吉林省教育厅“十三五”科学技术项目 (JJKH20170409KJ), 吉林省卫生计生厅创新项目 (2017J104) 资助, 大学生创新创业训练计划项目 (201713743010) 资助 (The National Natural Science Foundation of China (21102055); Department of education of Jilin province (JJKH20170409KJ); Health Department of Jilin province (2017J104); National Students' program for Innovation and Entrepreneurship Training (201713743010)).

作者简介: 王黎明 (1980-) 男, 硕士研究生, 研究方向: 有机合成及不对称催化. (Li ming Wang (1980-), male; Master's degree; researching field: organic synthesis and asymmetric catalysis).

* 通讯联系人, E-mail: jinying2288@163.com.


1 实验部分

1.1 试剂和仪器

Bruker Avance-500 型核磁共振谱仪(均以 CDCl_3 为溶剂, TMS 为基准物质, 德国 Bruker 公司); MICROMASS Quattro Premier 型质谱仪(美国 waters 公司); LC-20A 高效液相色谱仪(日本岛津公司), Daicel Chiralpak AD-H, Chiralcel OD-H 手性色谱柱(日本大赛璐公司). 豚及硫豚衍生物为上海大赛璐药物手性技术(上海)有限公司产品, 其他试剂均为市售分析纯产品.

1.2 不对称 Michael 加成反应

于 5 mL 圆底烧瓶中依次加入反式硝基苯乙烯 (29.8 mg, 0.2 mmol), 催化剂 (0.01 mmol), 蒽酮 (46.6 mg, 0.24 mmol), 二氯甲烷 3.0 mL, 室温搅拌反应 12~18 h, TLC 监测. 反应完毕后, 经硅胶柱层析分离, Hex: EtOAc (9:1) 洗脱, 得到产品 **3a-m**.



10-(2-硝基-1-苯基乙基)-10H-蒽-9-酮 **3a**: 白色固体; mp = 145~147 °C, [文献值^[28] mp = 146.8~149.0 °C]; ^1H NMR (500 MHz, CDCl_3) δ 8.07 (d, $J = 8.0$ Hz, 1H), 7.98 (d, $J = 8.0$ Hz, 1H), 7.67-7.59 (m, 2H), 7.53-7.46 (m, 2H), 7.45-7.40 (m, 2H), 7.17-7.13 (m, 1H), 6.95 (t, $J = 7.5$ Hz, 2H), 6.05 (d, $J = 8.0$ Hz, 2H), 4.89 (dd, $J = 9.0, 13.0$ Hz, 1H), 4.60 (dd, $J = 7.0, 13.0$ Hz, 1H), 4.55 (d, $J = 3.5$ Hz, 1H), 4.08-4.04 (m, 1H); HPLC (Daicel Chiralpak AD-H, $V_{\text{hex}} : V_{i\text{PrOH}} = 97 : 3$, 0.6 mL/min, 254 nm), t_{R} : 45.9 min (major), 51.6 min (minor). $[\alpha]_{\text{D}}^{25} = +23.9$ ($c = 0.50$ in CHCl_3), 文献值^[28] $[\alpha]_{\text{D}}^{20} = +25.4$ ($c = 0.48$ in CHCl_3).

10-[1-(2-氟苯基)-2-硝基乙基]-10H-蒽-9-酮 **3b**: 白色固体; mp = 117~119 °C; ^1H NMR (500 MHz, CDCl_3) δ 8.13 (d, $J = 7.5$ Hz, 1H), 8.07 (d, $J = 7.5$ Hz, 1H), 7.66-7.61 (m, 1H), 7.57-7.49 (m, 3H), 7.48-7.44 (m, 1H), 7.26-7.18 (m, 2H), 6.88-6.78 (m, 2H), 6.07 (t, $J = 7.5$ Hz,

1H), 4.74 (dd, $J = 8.0, 13.5$ Hz, 1H), 4.60 (d, $J = 9.0, 1H$), 4.54 (dd, $J = 8.0, 13.5$ Hz, 1H), 4.39-4.35 (m, 1H); HPLC (Daicel Chiralpak AD-H, $V_{\text{hex}} : V_{i\text{PrOH}} = 97 : 3$, 0.6 mL/min, 254 nm), t_{R} : 54.4 min (major), 64.1 min (minor). $[\alpha]_{\text{D}}^{25} = +17.5$ ($c = 0.55$ in CHCl_3).

10-[1-(2-氯苯基)-2-硝基乙基]-10H-蒽-9-酮 **3c**: 白色固体; mp = 123~124 °C, [文献值^[27] mp = 126.2~126.7 °C]; ^1H NMR (500 MHz, CDCl_3) δ 8.18 (d, $J = 7.5$ Hz, 1H), 8.15 (d, $J = 7.5$ Hz, 1H), 7.70-7.64 (m, 2H), 7.54-7.51 (m, 1H), 7.47-7.43 (m, 1H), 7.42-7.35 (m, 2H), 7.23-7.19 (m, 1H), 7.02 (t, $J = 7.5$ Hz, 1H), 6.80 (d, $J = 7.0$ Hz, 1H), 6.23 (d, $J = 8.0$ Hz, 1H), 4.72 (bs, 1H), 4.66 (d, $J = 3.5$ Hz, 1H), 4.44-4.38 (m, 2H); HPLC (Daicel Chiralpak AD-H, $V_{\text{hex}} : V_{i\text{PrOH}} = 97 : 3$, 0.6 mL/min, 254 nm), t_{R} : 33.4 min (major), 53.9 min (minor). $[\alpha]_{\text{D}}^{25} = +18.6$ ($c = 0.60$ in CHCl_3), 文献值^[28] $[\alpha]_{\text{D}}^{20} = +14.8$ ($c = 0.54$ in CHCl_3).

10-[1-(2-溴苯基)-2-硝基乙基]-10H-蒽-9-酮 **3d**: 白色固体; mp = 100~102 °C, [文献值^[28] mp = 62.8~65.6 °C]; ^1H NMR (500 MHz, CDCl_3) δ 8.22-8.18 (m, 2H), 7.80 (bs, 1H), 7.71-7.68 (m, 1H), 7.61 (d, $J = 6.5$ Hz, 1H), 7.55 (t, $J = 7.5$ Hz, 1H), 7.49-7.45 (m, 1H), 7.38 (t, $J = 7.5$ Hz, 1H), 7.17-7.13 (m, 1H), 7.07 (t, $J = 7.5$ Hz, 1H), 6.72-6.71 (m, 1H), 6.25 (dd, $J = 1.5, 8.0$ Hz, 1H), 4.73 (bs, 1H), 4.72 (s, 1H), 4.36 (d, $J = 6.0$ Hz, 2H); HPLC (Daicel Chiralpak AD-H, $V_{\text{hex}} : V_{i\text{PrOH}} = 97 : 3$, 0.6 mL/min, 254 nm), t_{R} : 42.3 min (major), 61.9 min (minor). $[\alpha]_{\text{D}}^{25} = +8.0$ ($c = 0.53$ in CHCl_3), 文献值^[28] $[\alpha]_{\text{D}}^{20} = +7.1$ ($c = 0.74$ in CHCl_3).

10-[1-(3-氟苯基)-2-硝基乙基]-10H-蒽-9-酮 **3e**: 白色固体; mp = 128~130 °C, [文献值^[28] mp = 123.8~126.9 °C]; ^1H NMR (500 MHz, CDCl_3) δ 8.09 (d, $J = 7.5$ Hz, 1H), 8.02 (d, $J = 7.5$ Hz, 1H), 7.69-7.59 (m, 2H), 7.55-7.40 (m, 4H), 6.98-6.82 (m, 2H), 5.88 (d, $J = 7.5$ Hz, 1H), 5.80-5.76 (m, 1H), 4.86 (dd, $J = 8.5, 13.5$ Hz, 1H), 4.59 (dd, $J = 8.5, 13.5$ Hz, 1H), 4.55 (d, $J = 3.5$ Hz, 1H), 4.08-4.02 (m, 1H); HPLC

(Daicel Chiralpak AD-H, $V_{\text{hex}} : V_{i\text{PrOH}} = 97 : 3$, 0.6 mL/min, 254 nm), t_{R} : 65.9 min (major), 71.9 min (minor). $[\alpha]_{\text{D}}^{25} = +28.5$ ($c = 0.52$ in CHCl_3), 文献值^[28] $[\alpha]_{\text{D}}^{20} = +26.3$ ($c = 0.58$ in CHCl_3).

10-[1-(3-溴苯基)-2-硝基乙基]-10*H*-蒽-9-酮 **3f**: 白色固体; mp = 120 ~ 121 °C, [文献值^[28] mp = 114.7 ~ 117.1 °C]; ¹H NMR (500 MHz, CDCl_3) δ 8.11 (d, $J = 7.5$ Hz, 1H), 8.02 (d, $J = 7.5$ Hz, 1H), 7.69-7.60 (m, 2H), 7.56-7.41 (m, 4H), 7.27 (d, $J = 9.0$ Hz, 1H), 6.83 (t, $J = 8.0$ Hz, 1H), 6.14 (s, 1H), 6.01 (d, $J = 7.5$ Hz, 1H), 5.96 (d, $J = 7.5$ Hz, 1H), 4.85 (dd, $J = 8.5$, 13.5 Hz, 1H), 4.59-4.54 (m, 2H), 4.04-3.98 (m, 1H); HPLC (Daicel Chiralpak AD-H, $V_{\text{hex}} : V_{i\text{PrOH}} = 97 : 3$, 0.6 mL/min, 254 nm), t_{R} : 59.6 min (major), 73.7 min (minor). $[\alpha]_{\text{D}}^{25} = +35.2$ ($c = 0.42$ in CHCl_3), 文献值^[28] $[\alpha]_{\text{D}}^{20} = +31.0$ ($c = 0.58$ in CHCl_3).

10-[1-(3-甲基苯基)-2-硝基乙基]-10*H*-蒽-9-酮 **3g**: 白色固体; mp = 107 ~ 109 °C, [文献值^[28] mp = 111.5 ~ 113.9 °C]; ¹H NMR (500 MHz, CDCl_3) δ 8.06 (d, $J = 8.0$ Hz, 1H), 7.97 (d, $J = 8.0$ Hz, 1H), 7.66-7.58 (m, 2H), 7.52-7.47 (m, 2H), 7.43-7.38 (m, 2H), 6.95 (d, $J = 7.5$ Hz, 1H), 6.82 (t, $J = 7.5$ Hz, 1H), 5.86 (d, $J = 7.5$ Hz, 1H), 5.77 (s, 1H), 4.85 (dd, $J = 9.0$, 13.0 Hz, 1H), 4.57 (dd, $J = 7.0$, 13.5 Hz, 1H), 4.52 (d, $J = 3.5$ Hz, 1H), 4.01-3.98 (m, 1H), 2.02 (s, 3H); HPLC (Daicel Chiralpak AD-H, $V_{\text{hex}} : V_{i\text{PrOH}} = 97 : 3$, 0.6 mL/min, 254 nm), t_{R} : 36.1 min (major), 53.0 min (minor). $[\alpha]_{\text{D}}^{25} = +37.1$ ($c = 0.45$ in CHCl_3), 文献值^[28] $[\alpha]_{\text{D}}^{20} = +33.2$ ($c = 0.60$ in CHCl_3).

10-[1-(4-氟苯基)-2-硝基乙基]-10*H*-蒽-9-酮 **3h**: 白色固体; mp = 165 ~ 167 °C, [文献值^[28] mp = 170.1 ~ 172.0 °C]; ¹H NMR (500 MHz, CDCl_3) δ 8.08 (d, $J = 7.5$ Hz, 1H), 8.00 (d, $J = 7.5$ Hz, 1H), 7.67-7.60 (m, 2H), 7.53-7.42 (m, 4H), 6.64 (d, $J = 7.5$ Hz, 2H), 6.02-5.99 (m, 2H), 4.87 (dd, $J = 9.0$, 13.0 Hz, 1H), 4.59-4.52 (m, 2H), 4.06-4.02 (m, 1H); HPLC (Daicel Chiralpak AD-H, $V_{\text{hex}} : V_{i\text{PrOH}} = 97 : 3$, 0.6 mL/min,

254 nm), t_{R} : 53.3 min (major), 58.6 min (minor). $[\alpha]_{\text{D}}^{25} = +33.5$ ($c = 0.65$ in CHCl_3), 文献值^[28] $[\alpha]_{\text{D}}^{20} = +31.0$ ($c = 0.46$ in CHCl_3).

10-[1-(4-氯苯基)-2-硝基乙基]-10*H*-蒽-9-酮 **3i**: 白色固体; mp = 170 ~ 172 °C, [文献值^[28] mp = 168.7 ~ 171.2 °C]; ¹H NMR (500 MHz, CDCl_3) δ 8.11 (d, $J = 8.0$ Hz, 1H), 8.03 (d, $J = 8.0$ Hz, 1H), 7.68-7.59 (m, 2H), 7.54-7.44 (m, 3H), 7.40 (d, $J = 7.5$ Hz, 1H), 6.95 (d, $J = 8.5$ Hz, 2H), 6.02 (d, $J = 8.0$ Hz, 2H), 4.85 (dd, $J = 8.5$, 13.0 Hz, 1H), 4.57-4.52 (m, 2H), 4.06-4.02 (m, 1H); HPLC (Daicel Chiralpak AD-H, $V_{\text{hex}} : V_{i\text{PrOH}} = 97 : 3$, 0.6 mL/min, 254 nm), t_{R} : 41.9 min (major), 47.5 min (minor). $[\alpha]_{\text{D}}^{25} = +24.3$ ($c = 0.50$ in CHCl_3), 文献值^[28] $[\alpha]_{\text{D}}^{20} = +21.7$ ($c = 0.40$ in CHCl_3).

10-[1-(4-甲基苯基)-2-硝基乙基]-10*H*-蒽-9-酮 **3j**: 白色固体; mp = 158 ~ 160 °C, [文献值^[28] mp = 156.0 ~ 158.1 °C]; ¹H NMR (500 MHz, CDCl_3) δ 8.08 (d, $J = 7.5$ Hz, 1H), 8.00 (d, $J = 7.5$ Hz, 1H), 7.67-7.58 (m, 2H), 7.53-7.49 (m, 2H), 7.45-7.38 (m, 2H), 6.76 (d, $J = 8.0$ Hz, 2H), 5.96 (d, $J = 8.0$ Hz, 2H), 4.84 (dd, $J = 9.0$, 13.0 Hz, 1H), 4.57-4.52 (m, 2H), 4.05-4.00 (m, 1H), 2.22 (s, 3H); HPLC (Daicel Chiralpak AD-H, $V_{\text{hex}} : V_{i\text{PrOH}} = 97 : 3$, 0.6 mL/min, 254 nm), t_{R} : 34.0 min (major), 36.3 min (minor). $[\alpha]_{\text{D}}^{25} = +28.9$ ($c = 0.56$ in CHCl_3), 文献值^[28] $[\alpha]_{\text{D}}^{20} = +25.4$ ($c = 0.62$ in CHCl_3).

10-[1-(4-硝基苯基)-2-硝基乙基]-10*H*-蒽-9-酮 **3k**: 白色固体; mp = 189 ~ 191 °C, [文献值^[28] mp = 194.5 ~ 196.1 °C]; ¹H NMR (500 MHz, CDCl_3) δ 9.90 (d, $J = 7.5$ Hz, 1H), 7.85-7.69 (m, 6H), 7.58-7.48 (m, 3H), 6.46 (d, $J = 8.5$ Hz, 2H), 5.47 (dd, $J = 5.0$, 13.5 Hz, 1H), 5.06 (dd, $J = 10.0$, 13.5 Hz, 1H), 4.95 (d, $J = 4.0$ Hz, 1H), 4.15-4.10 (m, 1H); HPLC (Chiralpak AD-H, $V_{\text{hex}} : V_{i\text{PrOH}} = 70 : 30$, 1.0 mL/min, 254 nm), t_{R} : 12.7 min (major), 16.9 min (minor). $[\alpha]_{\text{D}}^{25} = +25.1$ ($c = 0.55$ in CHCl_3), 文献值^[28] $[\alpha]_{\text{D}}^{20} = +21.2$ ($c = 0.42$ in CHCl_3).

10-[1-(4-甲氧基苯基)-2-硝基乙基]-10*H*-蒽-

9- 酮 **3l**: 白色固体; mp = 117~119 °C, [文献值^[28] mp = 119.8 ~ 122.7 °C]; ¹H NMR (500 MHz, CDCl₃) δ 8.07 (d, *J* = 8.0 Hz, 1H), 7.99 (d, *J* = 7.5 Hz, 1H), 7.66-7.65 (m, 2H), 7.50-7.38 (m, 4H), 6.47 (d, *J* = 8.5 Hz, 2H), 5.95 (d, *J* = 8.5 Hz, 2H), 4.83 (dd, *J* = 9.0, 13.0 Hz, 1H), 4.55 (dd, *J* = 8.0, 13.0 Hz, 1H), 4.49 (d, *J* = 3.5 Hz, 1H), 4.03-3.97 (m, 1H), 3.68 (s, 3H); HPLC (Chiralcel OD-H, *V*_{hex} : *V*_{iPrOH} = 70 : 30, 1.0 mL/min, 254 nm), *t*_R: 21.5 min (major), 29.2 min (minor). [α]_D²⁵ = +20.8 (*c* = 0.38 in CHCl₃), 文献值^[28] [α]_D²⁰ = +18.7 (*c* = 0.74 in CHCl₃).

10-[1-环己基-2- 硝基乙基]-10*H*-蒽-9-酮 **3m**: 白色固体; mp = 123~125 °C, [文献值^[28] mp = 127.3~130.8 °C]; ¹H NMR (500 MHz, CDCl₃) δ 8.30 (t, *J* = 8.5 Hz, 2H), 7.67-7.60 (m, 2H), 7.57-7.42 (m, 4H), 4.45 (dd, *J* = 9.0, 13.0 Hz, 1H), 4.35 (d, *J* = 2.5 Hz, 1H), 4.27 (dd, *J* = 5.0, 13.0 Hz, 1H), 2.73-2.65 (m, 1H), 1.62-1.48 (m, 2H), 1.44-1.35 (m, 2H), 1.20-1.02 (m, 3H), 0.97-0.75 (m, 2H), 0.45-0.25 (m, 2H); HPLC (Chiralpak AD-H, *V*_{hex} : *V*_{iPrOH} = 80 : 20, 1.0 mL/min, 254 nm), *t*_R: 8.9 min (major), 9.4 min (minor). [α]_D²⁵ = +63.6 (*c* = 0.40 in CHCl₃), 文献值^[28] [α]_D²⁰ = +61.0 (*c* = 0.24 in CHCl₃).

2 结果与讨论

2.1 催化剂 **1a-g** 催化不对称 Michael 加成反应

将催化剂 **1a-g** 用于反式硝基苯乙烯与蒽酮的不对称 Michael 加成反应, 以二氯甲烷为溶剂, 室温反应, 考察催化剂的催化性能, 结果见表 1.

由表 1 反应结果可以得出以下结论: 7 种(硫)脒类催化剂在二氯甲烷中均能顺利催化硝基苯乙烯与蒽酮的不对称 Michael 加成反应, 得到 80%~92% 的产率. 其中硫脒催化剂 **1f** 催化该反应得到了最好的对映选择性(85% ee, entry 6), 产品的构型, 通过测定旋光值, 对比文献报道^[27] 的旋光值确定主要产物的构型为 *S* 型.

2.2 反应条件的优化

将上述最好的催化剂 **1f** 用于硝基苯乙烯与蒽酮的不对称 Michael 加成反应中, 考察溶剂、温度、




表 1 反式硝基苯乙烯和蒽酮的不对称 Michael 加成反应结果^a

Table 1 Asymmetric Michael addition of nitrostyrene and anthrone^a

Entry	Catalyst	Yield/% ^b	% ee ^c	Conf. ^d
1	1a	80	69	<i>R</i>
2	1b	92	61	<i>R</i>
3	1c	90	53	<i>S</i>
4	1d	87	65	<i>S</i>
5	1e	90	27	<i>S</i>
6	1f	89	85	<i>S</i>
7	1g	88	55	<i>S</i>

- a. All of the reactions were performed with nitroalkenes 0.20 mmol, anthrone 0.24 mmol; b. Isolated yield; c. Determined by HPLC analysis (Chiralpak AD-H); d. The configuration was established by comparison with the optical rotation from the literature^[27].

催化剂用量等因素对反应立体选择性的影响, 以期获得更好的催化剂体系. 结果见表 2.

由表 2 结果可以看出: (1) 溶剂对反应的立体选择性有显著影响, 其中二氯甲烷和氯仿作为溶剂均得到了最好的 ee 值(entries 1,8). 考虑到氯仿溶剂的毒性大, 选择二氯甲烷为溶剂; (2) 降温对反应的立体选择性没有改善, 反应温度由室温降至 0 °C, 反应的立体选择性明显降低(entry 11vs entry 1); (3) 催化剂的用量由 10%(摩尔百分数)增加至 20%或降至 5%, 反应的对映体过量值均增加了 6%(entries 9,10 vs entry 1), 反应产率以 20%(摩尔百分数)用量时略高. 但是, 考虑到催化剂用量越少, 反应的成本越低, 因此, 选择 5%(摩尔百分数)的催化剂用量, 以及延长反应时间来提高反应产率; (4) 当反应溶剂量加倍, 既反应体系稀释条件下, 反应的产率和立体选择性都有所下降. 综上所述, 筛选出的最佳催化剂体系为: 5%(摩尔百分数)的催化剂 **1f**, 二氯甲烷为溶剂, 室温反应.

表 2 反式硝基苯乙烯与蒽酮的不对称 Michael 加成反应条件筛选^a

Table 2 Screening of Reaction Conditions for the Asymmetric Michael Addition Reaction^a

Entry	Solvent	Cat.ammount/(% mol)	Temp./℃	Yield/% ^b	/ %ee ^c
1	CH ₂ Cl ₂	10	rt	92	85
2	toluene	10	rt	80	71
3	CH ₃ CN	10	rt	75	41
4	C ₂ H ₄ Cl ₂	10	rt	82	83
5	THF	10	rt	90	63
6	EA	10	rt	83	75
7	Et ₂ O	10	rt	85	67
8	CHCl ₃	10	rt	93	85
9	CH₂Cl₂	5	rt	92	91
10	CH₂Cl₂	20	rt	95	91
11	CH ₂ Cl ₂	10	0	85	55
12 ^d	CH ₂ Cl ₂	5	rt	87	82

a. All of the reactions were performed with nitroalkenes 0.20 mmol, anthrone 0.24 mmol; b. Isolated yield; c. Determined by HPLC analysis (Chiralpak AD-H); d. Solvent was double.

2.3 底物的扩展

将筛选出的催化条件应用于不同取代β硝基芳

基乙烯的不对称 Michael 加成反应，考察催化剂体系的普适性，结果见表 3.




表 3 蒽酮和不同硝基烯烃的不对称 Michael 加成反应^a

Table 3 Asymmetric Michael Addition Reactions of Anthrone to Various Nitroalkenes^a

Entry	R	Product	Yield/% ^b	%ee ^c
1	Ph	3a	90	91
2	2-F-Ph	3b	97	99
3	2-Cl-Ph	3c	90	96
4	2-Br-Ph	3d	92	87
5	3-F-Ph	3e	92	94
6	3-Br-Ph	3f	93	88
7	3-CH₃-Ph	3g	91	99
8	4-F-Ph	3h	92	90
9	4-Cl-Ph	3i	91	95
10	4-CH ₃ -Ph	3j	95	91
11	4-NO ₂ -Ph	3k	90	87
12	4-OMe-Ph	3l	91	91
13	cC ₆ H ₁₁ -	3m	80	86

a. All of the reactions were performed with nitroalkenes 0.20 mmol, anthrone 0.24 mmol in toluene 3 mL; b. Isolated yield; c. Determined by HPLC (Chiralpak AD-H, Chiralcel OD-H).

实验结果表明: 催化剂 **1f** 能够顺利地催化不同取代硝基乙烯为底物的反应, 得到 80%~97% 的产率. 并表现出优良的立体选择性 (86%~99% ee), 其中以 2-氟及 3-甲基取代的底物获得了最高的对映体过量值 (99% ee, entries 2, 7).

3 结论

我们将硫脲衍生物用于有机催化蒽酮与硝基烯烃的不对称 Michael 加成反应, 筛选出最佳的催化体系, 并将其应用于 13 种硝基烯烃和蒽酮的反应, 均得到很好的化学产率和最高达 99% ee 的立体选择性. 催化剂体系对该反应表现出优秀的普适性.

参考文献:

- [1] Perlmutter P. Conjugate Addition Reactions in Organic Synthesis [M]. Oxford UK: Pergamon, Oxford press, 1992.
- [2] Wang Lei (王磊), Du Chuang (杜创), Ji Teng-fei (吉腾飞), *et al.* Study on the enzymatic michael addition of uracil to ethyl acrylate (酶促尿嘧啶与丙烯酸乙酯 Michael 加成反应的研究) [J]. *J Mol Catal (China)* (分子催化), 2008, **22**(2): 172-176.
- [3] Wei Xiao-fei (魏晓飞), Du Chuang (杜创), Wang Ren (王任), *et al.* Study on the enzymatic michael addition in ionic liquids (离子液体中酶促 Michael 加成反应的研究) [J]. *J Mol Catal (China)* (分子催化), 2009, **23**(3): 273-276.
- [4] Krishna P R, Sreeshailam A, Srinivas R. Recent advances and applications in asymmetric aza-michael addition chemistry [J]. *Tetrahedron*, 2009, **65**(47): 9657-9672.
- [5] Enders D, Wang C, Liebich J X. Organocatalytic asymmetric aza-michael additions [J]. *Chem Eur J*, 2009, **15**(42): 11058-11076.
- [6] Li Ning (李宁), Xi Guo-hong (郗国宏), Wu Qiu-hua (吴秋华), *et al.* Organocatalytic asymmetric michael additions (有机催化不对称 Michael 加成反应) [J]. *Chin J Org Chem (China)* (有机化学), 2009, **29**(7): 1018-1038.
- [7] Ying An-guo (应安国), Wu Cheng-lin (吴承林), Fu Yong-qin (付永前), *et al.* Progress in the application of organocatalysis to asymmetric michael additions (有机小分子不对称催化 Michael 加成的研究进展) [J]. *Chin J Org Chem (China)* (有机化学), 2012, **32**(9): 1587-1604.
- [8] Liu K, Cui H F, Nie J, *et al.* Highly enantioselective michael addition of aromatic ketones to nitroolefins promoted by chiral bifunctional primary amine-thiourea catalysts based on saccharides [J]. *Org Lett*, 2007, **9**(5): 923-925.
- [9] Li P F, Wang Y C, Liang X M, *et al.* Asymmetric multi-functional organocatalytic michael addition of nitroalkanes to α,β -unsaturated ketones [J]. *Chem Commun*, 2008, **44**(28): 3302-3304.
- [10] Peng F Z, Shao Z H, Fan B M, *et al.* Organocatalytic enantioselective michael addition of 2,4-pentandione to nitroalkenes promoted by bifunctional thioureas with central and axial chiral elements [J]. *J Org Chem*, 2008, **73**(13): 5202-5205.
- [11] Zhou W M, Liu H, Du D M. Organocatalytic highly enantioselective michael addition of 2-hydroxy-1,4-naphthoquinones to nitroalkenes [J]. *Org Lett*, 2008, **10**(13): 2817-2820.
- [12] Dong X Q, Teng H L, Wang C J. Highly enantioselective direct michael addition of nitroalkanes to nitroalkenes catalyzed by amine-thiourea bearing multiple hydrogen-bonding donors [J]. *Org Lett*, 2009, **11**(6): 1265-1268.
- [13] Li P F, Wen S G, Yu F, *et al.* Enantioselective organocatalytic michael addition of malonates to α,β -unsaturated ketones [J]. *Org Lett*, 2009, **11**(3): 753-756.
- [14] Baslé O, Raimondi W, Duque M M S, *et al.* Highly diastereo- and enantioselective organocatalytic michael addition of α -ketoamides to nitroalkenes [J]. *Org Lett*, 2010, **12**(22): 5246-5249.
- [15] Hong B H, Kotame P, Lee G S. Asymmetric synthesis of 3,4-dihydrocoumarin motif with an all-carbon quaternary stereocenter *via* a michael-acetalization sequence with bifunctional amine-thiourea organocatalysts [J]. *Org Lett*, 2011, **13**(21): 5758-5761.
- [16] Jörres M, Schiffrers I, Atodiresei I, *et al.* Asymmetric michael additions of α -nitrocyclohexanone to aryl nitroalkenes catalyzed by natural amino acid-derived bifunctional thioureas [J]. *Org Lett*, 2012, **14**(17): 4518-4521.
- [17] Qiao B Q, An Y Q, Liu Q, *et al.* Organocatalytic asymmetric michael addition of 5*h*-oxazol-4-ones to nitroolefins [J]. *Org Lett*, 2013, **15**(10): 2358-2361.
- [18] Fang X, Li J, Wang C J. Organocatalytic asymmetric sulfa-michael addition of thiols to α,β -unsaturated hexafluoroisopropyl esters: expeditious access to (*R*)-thiazesim [J]. *Org Lett*, 2013, **15**(13): 3448-3451.
- [19] Cui B D, Han W Y, Wu Z J, *et al.* Enantioselective synthesis of quaternary 3-aminooxindoles via organocatalytic

- asymmetric michael addition of 3-monosubstituted 3-aminoindoles to nitroolefins [J]. *J Org Chem*, 2013, **78**(17): 8833–8839.
- [20] Zhao Y L, Wang Y, Cao J, *et al.* Organocatalytic asymmetric michael-michael cascade for the construction of highly functionalized *n*-fused piperidinoindoline derivatives [J]. *Org Lett*, 2014, **16**(9): 2438–2441.
- [21] Farley A J M, Sandford C, Dixon D J. Bifunctional iminophosphorane catalyzed enantioselective sulfa-michael addition to unactivated α -substituted acrylate esters [J]. *J Am Chem Soc*, 2015, **137**(51): 15992–15995.
- [22] Saha P, Biswas A, Molleti N, *et al.* Enantioselective synthesis of highly substituted chromans via the oxa-michael-michael cascade reaction with a bifunctional organocatalyst [J]. *J Org Chem*, 2015, **80**(21): 11115–11122.
- [23] Jin H, Kim S T, Hwang G S, *et al.* L-proline derived bifunctional organocatalysts: Enantioselective michael addition of dithiomalonates to *trans*- β -nitroolefins [J]. *J Org Chem*, 2016, **81**(8): 3263–3274.
- [24] Zhang J, Yin G H, Du Y C, *et al.* Michael-michael addition reactions promoted by secondary amine-thiourea: Stereocontrolled construction of barbiturate-fused tetrahydropyrano scaffolds and pyranocoumarins [J]. *J Org Chem*, 2017, **82**(24): 13594–13601.
- [25] Shen J, Nguyen T T, Goh Y P, *et al.* Chiral bicyclic guanidine-catalyzed enantioselective reactions of anthrones [J]. *J Am Chem Soc*, 2006, **128**(4): 13692–13693.
- [26] Alba A -N, Bravo N, Moyano A, *et al.* Enantioselective addition of anthrones to α, α -unsaturated aldehydes [J]. *Tetra Lett*, 2009, **50**(25): 3067–3069.
- [27] Shi M, Lei Z Y, Zhao M X, *et al.* A highly efficient asymmetric Michael addition of anthrone to nitroalkenes with cinchona organocatalysts [J]. *Tetra Lett*, 2007, **48**(33): 5743–5746.
- [28] Liao Y H, Zhang H, Wu Z, *et al.* Enantioselective michael addition of anthrone to nitroalkenes catalyzed by bifunctional thiourea-tertiary amines [J]. *Tetra: Asy*, 2009, **20**(12): 2397–2402.
- [29] HE T X, Wu X Y. Enantioselective organocatalytic michael addition of anthrone to nitroalkenes [J]. *Chin J Org Chem (China)* (有机化学), 2010, **30**(9): 1400–1404.
- [30] Zhang Tian-yi (张天一), Nian Wen-xia (年文霞), Jin Ying (金 瑛). Organocatalysis asymmetric michael addition reaction of anthrone with β -nitro-arylethenes (有机催化蒽酮与 β -硝基芳基乙烯的不对称 Michael 加成反应) [J]. *Chin J Appl Chem (China)* (应用化学), 2015, **32**(4): 422–427.

Thiourea Derivatives Organocatalyzed Asymmetric Michael Addition Reaction of Anthrone with Nitroalkenes

WANG Li-ming, CHEN Zhe, ZHAO Mei-jun, JIN Ying*

(Department of Pharmacy, Jilin Medical University, Jilin 132013, China)

Abstract: The (thio) urea derivatives as organocatalysts were applied in asymmetric Michael addition reaction of anthrone with different nitroalkenes. The effect of solvent, temperature and catalyst loading amount were investigated. The optimized conditions were confirmed to include CH_2Cl_2 as the solvent with a 5% loading of catalyst **1f** at rt. The desired products were obtained in 80%~97% yield with up to 99% ee.

Key words: thiourea derivatives; organocatalysis; asymmetric Michael addition; anthrone; β -nitroalkenes

《分子催化》征稿启事

《分子催化》是由中国科学院主管、科学出版社出版,由中国科学院兰州化学物理研究所主办的向国内外公开发行的学术刊物.主要报导有关分子催化方面的最新进展与研究成果.辟有学术论文、研究简报、研究快报及进展评述等栏目.内容侧重于络合催化、酶催化、光助催化、催化过程中的立体化学问题、催化反应机理与动力学、催化剂表面态的研究及量子化学在催化学科中的应用等.工业催化过程中均相催化剂、固载化的均相催化剂、固载化的酶催化剂等的活化、失活和再生,以及用于新催化过程的催化剂的优选与表征等方面的稿件,本刊也很欢迎.读者对象主要是科研单位及工矿企业中从事催化工作的科技人员、研究生、高等院校化学系和化工系师生.欢迎相关专业人员投稿.

本刊为双月刊,每逢双月末出版,大16开本,约16万字,每册定价30.00元.中国标准刊号:ISSN 1001-3555/CN 62-1039/O6.邮发代号:54-69. E-mail信箱:FZCH@licp.cas.cn 网址:www.jmcchina.org 通过兰州市邮局发行.亦可向本刊编辑部直接函购.

来稿注意事项

1. 自由投稿,文责自负,来稿请附作者单位推荐信(负责稿件的保密审查).请勿一稿两投,勿将稿件寄给个人.
2. 来稿一式两份(微机打印稿).稿中外文字母应分清文种、大写、小写、上角、下角、正体、斜体,易混淆之处请注明.
3. 稿件应主题突出,论点明确,论据可靠,文字简练通顺.文稿形式包括:
 研究论文:一般不超过6000字(含图、表、200字的中文摘要和约2000印刷字符的英文摘要).
 研究简报:约4000字(含图、表及英文摘要).
 研究快报:中英文皆可,2500字左右(占两页版面),中文需提供简短的英文摘要.
4. 论文题目一般不超过20个字.应使用规范的缩略字、符号、代号,非常见的科技名词和化合物在第一次出现时应给出英文全称.并在正文前、英文摘要后,给出3~5个相对应的中、英文关键词.
5. 图、表应尽量精简.同时给出中、英文图题、表题,图、表中的注释用英文表示.
6. 参考文献的作者不超过3人时,全部列出;多于3人的一般只列主要3人,后加“等”或“et al”.本刊采用顺序编码制,格式如下:
 专著:作者.书名.版本(第1版不著录).出版地:出版者,出版年,起止页码
 期刊:作者.文题名.刊名,出版年,卷号(期号):起止页码
 论文集:作者.见:编者.论文集名.出版地:出版者,出版年,起止页码
 专利:专利申请者.题名.专利国别,专利号.年代
 * 中文文献全部用英(中)文方式列出,举例(期刊)如下:
 Zhong Shun-he(钟顺和), Kong Ling-li(孔令丽), Lei Ze(雷泽), et al. 文题名(注:一定要加文题名)[J]. *J Mol Catal(China)* (分子催化), 2002, 16(6):401-407.
 参考文献类型(文献类型标识):专著([M]) 论文集([C]) 报纸文章([N]) 期刊文章([J])
 学位论文([D]) 报告([R]) 标准([S]) 专利([P])
7. 文稿中的计量单位请采用我国法定计量单位.
8. 作者收到修改意见后,一般应在2个月内寄回修改稿,逾期请来信说明.
9. 本刊文稿中的中、英文摘要将由编辑部提供给有关文摘检索刊物编辑部及《中国学术期刊》(光盘版).如作者不同意提供,请在投稿时声明.
10. 来稿一经发表,即付稿酬,并赠送载有本文的期刊1本和10本抽印本.
11. 来稿请提供第一作者的个人信息:性别、出生年月、职称、学位.
12. 请作者提供修改稿电子版文件(要求用以下编辑及排版软件:Word、华光书版、北大方正).
 来稿请寄:甘肃兰州市中国科学院兰州化学物理研究所《分子催化》编辑部
 邮政编码 730000; 电话:(0931)-4968226; 传真:(0931)8277088.